Differentiation and reversal of malignant changes in colon cancer through PPARγ
- 1 September 1998
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 4 (9) , 1046-1052
- https://doi.org/10.1038/2030
Abstract
PPARγ is a nuclear receptor that has a dominant regulatory role in differentiation of cells of the adipose lineage, and has recently been shown to be expressed in the colon. We show here that PPARγ is expressed at high levels in both well- and poorly-differentiated adenocarcinomas, in normal colonic mucosa and in human colon cancer cell lines. Ligand activation of this receptor in colon cancer cells causes a considerable reduction in linear and clonogenic growth, increased expression of carcinoembryonic antigen and the reversal of many gene expression events specifically associated with colon cancer. Transplantable tumors derived from human colon cancer cells show a significant reduction of growth when mice are treated with troglitazone, a PPARγ ligand. These results indicate that the growth and differentiation of colon cancer cells can be modulated through PPARγ.Keywords
This publication has 26 references indexed in Scilit:
- Terminal Differentiation of Human Breast Cancer through PPARγMolecular Cell, 1998
- PPARγ induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2AGenes & Development, 1997
- Tissue Distribution and Quantification of the Expression of mRNAs of Peroxisome Proliferator–Activated Receptors and Liver X Receptor-α in Humans: No Alteration in Adipose Tissue of Obese and NIDDM PatientsDiabetes, 1997
- Peroxisome Proliferator-activated Receptors α and γ Are Activated by Indomethacin and Other Non-steroidal Anti-inflammatory DrugsJournal of Biological Chemistry, 1997
- Inhibition of Adipogenesis Through MAP Kinase-Mediated Phosphorylation of PPARγScience, 1996
- A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor γ and promotes adipocyte differentiationCell, 1995
- 15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγCell, 1995
- A synthetic inhibitor of the mitogen-activated protein kinase cascade.Proceedings of the National Academy of Sciences, 1995
- Improvement in Glucose Tolerance and Insulin Resistance in Obese Subjects Treated with TroglitazoneNew England Journal of Medicine, 1994
- Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.Proceedings of the National Academy of Sciences, 1994